INS and Hyperglycemia: Furthermore, targeting FPG with basal insulin in patients insufficiently controlled (HbA1c >7%) on oral agents has been shown to increase markedly the relative contribution of PPG to overall hyperglycaemia from 20–24% to 59–69% across the range of achieved HbA1c (including patients with HbA1c remaining ≥8%), highlighting the need to target PPG on top of FPG if further improvements are to be achieved 40.